Stifel analyst Rick Wise lowered the firm’s price target on Zimmer Biomet (ZBH) to $110 from $118 and keeps a Buy rating on the shares. The firm says the company’s Q3 performance was frustratingly more mixed than it anticipated. While Zimmer did make positive progress on multiple fronts, at the same time, management highlighted that several end-of-quarter Q3 international and noncore business headwinds pressured sales by about 120bps. Stifel thinks that the quarter also illustrated Zimmer Biomet’s commercial and innovation progress, factors that are not being considered in today’s stock performance.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target lowered to $112 from $122 at BTIG
- Morning Movers: Sleep Number, Pinterest plummet after earnings
- Zimmer Biomet reports Q3 adjusted EPS $1.90, consensus $1.86
- Zimmer Biomet backs FY25 adjusted EPS view $8.10-$8.30, consensus $8.14
- Zimmer Biomet price target lowered to $105 from $112 at Barclays